Takeda's Investigational Compound TAK-536 Enters into Phase 2 Clinical Stage in Japan
Takeda Pharmaceutical Company Limited ("Takeda") announced that its investigational compound TAK-536 has entered into Phase 2 clinical stage in Japan. TAK-536 is an angiotensin receptor blocker (ARB) discovered by Takeda and its mechanism of action is to lower blood pressure by inhibiting action of a vasopressor hormone Angiotensin II.
TAK-536 is expected to show stronger anti-hypertensive action, and also to have superior profile in improving the insulin resistance and renal protective action as compared to existing ARBs on the market.
"We are pleased with the progress of TAK-536's development stage into Phase 2 in Japan as this compound is expected to succeed Blopress® (generic name: candesartan cilexetil), which is an ARB and one of our international strategic products, and also is one of the leading anti-hypertensive products in Japan" said Masaomi Miyamoto, Ph.D., General Manager of Pharmaceutical Development Division of Takeda. "We are aiming to vigorously accelerate the development of TAK-536 for the earliest possible launch to further enhance our franchise in this therapeutic area."
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com/
Most Read News
- Radioactive bacteria targets metastatic pancreatic cancer
- Drug reduces fat by blocking blood vessels
- Fighting bacteria with a new genre of antibodies
- Experts discuss ways to embed patient voices and values in clinical research
- Hundreds of alterations and potential drug targets to starve cancer tumors identified
- AstraZeneca first quarter results 2013
- Bristol-Myers Squibb reports first quarter 2013 financial results
Company Profiles and News
Showcase your Company Profile / News
Pharmaceutical Companies
News in Pictures
Be on top of World Pharma News!
Advertise with us - Download World Pharma News' Media Pack Read more
Abbott Launches New Psoriasisanswers.com Web site
August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information Read more
AstraZeneca Headquarters, London
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, Read more
Site Roche Basel
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in Read more
Gehry building, Novartis headquarters in Basel, Switzerland
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving Read more
GSK Corporate HQ
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more
Sanofi-aventis Group head office
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: Read more
Boehringer Ingelheim Center, Ingelheim, Germany
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 Read more
Novo Nordisk's corporate headquarters in Bagsværd, Denmark
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth Read more
Business & Industry News
- AstraZeneca issues update on accelerated oncology pipeline
- GSK and Save the Children form unique partnership to save the lives of one million children
- Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis
- Amgen and Zhejiang Beta Pharma announce planned joint venture in China
- Boehringer Ingelheim joins Structural Genomics Consortium
- Real-world data at ARVO highlight transformational outcomes seen with Lucentis®
- Bristol-Myers Squibb and Pfizer announce publication of ARISTOTLE subanalysis in Circulation
Research & Development News
- Nanotechnology could help fight diabetes
- First prospective trial shows molecular profiling timely for tailoring therapy
- Breakthrough in how pancreatic cancer cells ingest nutrients points to new drug target
- New class of drug targets skin cancer
- Study opens new prospects for developing new targeted therapies for breast cancer
- Experts discuss ways to embed patient voices and values in clinical research
- Cancer studies often lack necessary rigor to answer key questions
Regulatory Affairs News
- FDA budget requests $4.7 billion
- FDA alerts health care providers of recall of anemia drug Omontys
- FDA approves Pomalyst for advanced multiple myeloma
- FDA approves Gleevec for children with acute lymphoblastic leukemia
- FDA approves new seasonal influenza vaccine made using novel technology
- FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation
- FDA expands use of Xarelto to treat, reduce recurrence of blood clots